Abstract: The invention herein relates to the use of nonpathogenic, anti-inflammatory and anti-bleeding lactic acid bacteria strains, and products and methods using such strains for treatment and prophylaxis of bleeding gum and gingivitis caused by oral inflammation.

Abstract: The present invention relates to a microorganism, preferably a bacterial strain, preferably a non-pathogenic strain, preferably a non-invasive strain, preferably a food grade strain, preferably a gram-positive bacterial strain, delivering a trefoil peptide in vivo. Preferably the trefoil peptide is TFF1. The present invention further relates to a method for the delivery of trefoil peptide to the gastro-intestinal tract comprising the administration of such a bacterial strain. The present invention also relates to a pharmaceutical composition comprising a trefoil peptide delivering bacterium as well as methods of treatment of acute gastro-intestinal inflammatory diseases comprising administration of transformed bacterial strains, particularly for treating acute colitis, including but not limited to acute flare-ups of Crohn's disease and ulcerative colitis in humans, as well as for treating gastro-intestinal disorders of a similar nature in other animal species.

Abstract: The invention relates to a cosmetic and/or dermatological topical composition, of particular use for the prevention al and/or treatment of sensitive and/or dry skin, comprising an effective amount of at least one particularly probiotic microorganism and/or a fraction or metabolite thereof in combination with an effective amount of at least one polyunsaturated fatty acid and/or polyunsaturated fatty acid ester and/or a salt or derivative thereof in a physiologically-acceptable vehicle.

Abstract: The present invention provides a composition which includes a sclareol or a derivative thereof, wherein the sclareol or a derivative thereof is bound by a glycoprotein matrix. The composition of the invention provides improved potency, stability and bioactivity characteristics of sclareol, or its derivatives.

Abstract: The present invention relates generally to the field of health promoting agents, in particular antimicrobial agents and provides antimicrobial peptides and bacterial strains that provide the antimicrobial peptides. In one aspect, the invention provides a biologically pure culture of Lactobacillus acidophilus, strain DPC6026, a sample of which has been deposited at the National Collection of Industrial and Marine Bacteria, Aberdeen, Scotland on 18th Nov. 2005 under the accession number NCIMB 41354, or a derivative or mutant thereof capable of producing from milk or a milk product, peptides having antimicrobial activity.

Abstract: According to the invention there is provided a strain of lactic acid bacteria of the genus Bifidobacteria obtainable by isolation from resected and washed feline gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Bifidobacteria of the present invention are also provided.

Abstract: Disclosed are a novel tactic acid bacterium, Lactobacillus sakei Probio-65, and the use thereof. The L. sakei Probio-65 strain has acid tolerance, bile acid tolerance and antibiotic resistance, inhibits the growth of harmful pathogenic microorganisms in the body and the intestine of animals, and has immunuenhancing activity. In particular, the novel strain inhibits the growth of Staphylocccus aureus, which is known to be a factor aggravating atopic dermatitis. Thus, the novel strain is useful for preventing or treating atopic dermatitis and allergy-related disorders. Also, the novel strain stabilizes intestinal microflors by inhibiting the abnormal proliferation of harmful microorganisms in the intestine. The L. sakei Probio-65 strain or a culture thereof is useful in pharmaceutical, feed, food, and cosmetic compositions.

Abstract: The present invention describes a process for the manufacture of a solid composition comprising a microorganism, which process comprises a first step of blending and/or compacting the microorganism with a salt of a medium or long-chain fatty acid to prepare a powderous mixture or compacted granulate, and a second step of providing said powderous mixture or compacted granulate with a coating. The microorganisms are preferably probiotics. The invention also relates to the solid composition obtained by said process and to its use in food.

Abstract: The present technology relates to the use of at least one strain of probiotic bacteria selected from Lactobacillus for the manufacture of a medicament for the treatment and/or prevention of an autoimmune disease.

Abstract: Disclosed herein are compositions for treating a respiratory condition, preferably by enhancing immune response in a mammal, the compositions including a therapeutic amount of a probiotic strain of bacteria and a therapeutic amount of an additional component. Also included are methods of treating a respiratory condition, preferably by enhancing immune response, in a mammal. Kits containing the compositions, and instructions for applying the methods are also included. The method includes orally administering to the mammal a therapeutic amount of a probiotic strain of bacteria and a therapeutic amount of an additional component.

Abstract: The invention concerns mutant L. bulgaricus strains bearing a nonsense mutation, in at least one of the sequences coding for the lactose operon, and free from ?-galactosidase activity, and lactic starters comprising these strains. The strains and starters can be used to obtain fermented milk products from glucose-added milk.

Abstract: A method is disclosed that prevents, controls and ameliorates urinary tract infections caused by E-coli by administering a therapeutically effective amount of a human dietary supplement composition comprising a cranberry derivative or proanthocyandin containing concentrate and D-mannose combined in a form suitable for oral consumption. The cranberry derivative or proanthocyandin containing concentrate comprises from about one percent (1.0%) by weight to about 95 percent (95.0%) by weight on a dry weight basis. The composition is formulated for delivering, a D-mannose unit dosage between about 0.5 to about 5.0 grams per dose and further comprising a diuretic and wherein the composition formed from the cranberry derivative or proanthocyandin containing concentrate, D-mannose and diuretic are effective together for binding to E-coli to aid in flushing the E-coli from the urinary tract system while preventing binding of E-coli to cells in the urinary tract system.

Abstract: The invention relates to the use of a product comprising a living Lactobacillus rhamnosus bacterium combined with lactose, particularly with a lactose-based medium, for the production of a medicament or a food supplement in order to treat a patient suffering from atopic dermatitis, in which said bacterium can ferment the lactose. In the preferred embodiments of the invention, the bacterium used originates from strain Lactobacillus rhamnosus Lcr35 and is used as a probiotic combined with a prebiotic that is, for example, based on lactose and optional metabolites resulting from the fermentation of the bacterium on the culture medium thereof, for the treatment of atopic dermatitis in children.

Abstract: A plant disease controlling agent containing a lactic acid bacterium which is capable of controlling plant disease and a plant disease controlling method which comprises treating a plant and/or soil with the above-mentioned lactic acid bacterium. By using the lactic acid bacterium seemingly advantageous to human health, an agricultural crop can be safely and stably produced. As the lactic acid bacterium as mentioned above, use may be favorably made of a microorganism belonging to the genus Pediococcus such as Pediococcus pentosaceus or a microorganism belonging to the genus Lactobacillus such as Lactobacillus plantarum.

Abstract: The invention relates to the use of at least one strain of lactic acid bacteria and/or bifidobacteria having hydrophobic surface properties, for the preparation of a composition intended for the prevention or the treatment of endotoxin mediated and/or associated disorders and human or pet food compositions prepared thereof.

Abstract: The present invention discloses an article with an antimicrobial property, and a manufacturing method thereof which gives the antimicrobial property to a surface of an article which bacteria or viruses may contact to proliferate themselves, by using the Kimchi lactic acid bacteria culture fluid with antibacterial and antivirus effects. The article needing the antimicrobial effect is provided with the antimicrobial property, by using the Kimchi lactic add bacteria culture fluid with a wide antibacterial spectrum singly or in combination with nano metal particles.

Abstract: The present invention is directed to a composition for use in liver function improvement, blood alcohol level reduction and in-vivo antioxidant activity enhancement, comprising Lactobacillus brevis HY7401, Lactobacillus fermentum CS332, Lactobacillus acidophilus CSG, Bifidobacterium longum HY8001, an Alder tree extract, a Selfheal extract, a milk thistle extract, a green bean-rice bran fermentation extract, a turnip extract, a tomato extract, a broccoli extract, a pineapple extract, a colostrum powder, betaine, vitamin B1, B2, B3, B6, B9, B12, C, and E. The composition can improve declined liver functions and shows excellent hepatoprotective and hepatocurative activity against alcohol on excessive or habitual drinking with the ability to reduce blood alcohol levels. Its superior enhancement of in-vivo antioxidant activity also contributes to the use of the composition in the prevention of liver diseases and the improvement of liver functions.

Abstract: The use of docosahexaenoic acid in the manufacture of a composition for administration to a pregnant woman for reducing the risk of development of overweight or obesity of the baby in infancy and/or early childhood.

Abstract: The present invention is related to an intravaginal delivery system for the controlled release of drospirenone and an estrogen, optionally also comprising one or more therapeutically active or a health-promoting substance capable of giving and/or enhancing protection against bacterial and fungal infections, and/or enhancing protection against sexually transmitted diseases. The delivery system consists of one or more compartments, one of each comprising a core and a membrane encasing the core, said core and membrane essentially consisting of a same or different polymer composition, wherein at least one compartment comprises drospirenone ant at least one compartment which may be the same or different from the one comprising drospirenone, comprises an estrogen or a mixture of drospirenone and an estrogen, and wherein the membrane or the surface of the membrane or at least one of the cores comprises said therapeutically active or a health-promoting substance.

Abstract: The present invention relates to the field of human health and uses of L. rhamnosus strains for the preparation of pharmaceutical and nutritional compositions.

Abstract: A mutant of Lactococcus lactis spp. lactis, which produces lactate at high volumetric and specific productivity as well as high amounts of lactate dehydrogenase, as well as the use of said strain, and a method for producing lactate, as well as the use of the lactate thus produced.

Abstract: In accordance with the present invention, there is provided a probiotic composition comprising an effective amount of Lactobacillus kefiranofaciens in association with a suitable carrier. The probiotic composition has many probiotic effects such as intestinal adherence, intestinal persistence, positive modulation of the intestinal microflora, protection against intestinal pathogens, immunomodulation, protection against systemic inflammation, protection against intestinal inflammation, protection against allergies, protection against diarrhea, protection against diabetes, protection against hyperlipidemia and protection against colon cancer. In accordance with the present invention, there is also provided a method of treatment and/or prevention of a number of diseases for which the composition has a beneficial effect.

Abstract: Described are microorganisms which are able to inhibit the formation of foot malodor by skin microorganisms. Also described are compositions comprising such microorganisms as well as the use of such microorganisms in cosmetic, prophylactic or therapeutic applications.

Abstract: New strains of Lactobacillus that have been selected for their capability of improved reduction the number of Streptococcus mutans in the mouth of mammals through inhibiting activity in combination with better binding to the oral mucins and dental plaque, thereby preventing, reducing or treating dental caries, and products derived from said strains, including agents for treatment or prophylaxis of caries for administration to humans.

Abstract: Provided are probiotic compositions that have enhanced stability under various storage conditions. The stability of the probiotic compositions is enhanced through the addition of various agents and excipients. Examples of agents and excipients that may be used to enhance the stability of probiotic compositions include prebiotics, such as the sugar alcohols mannitol, sorbitol, and lactitol, and/or phytonutrients such as oligomeric proanthocyanidins (OPCs). The probiotic compositions may be formulated into oral dosage forms such as tablets, caplets, and capsules, or manufactured as a chewing gum or as a powder formulation that may be dissolved in a liquid such as water, milk, juice, or yogurt.

Abstract: A composition and method for treatment for bowel disorders is described. The composition consists of two parts. First, highly purified, insoluble, chemically unmodified fiber from plants is mixed with an aqueous solution such as water. The second component of the composition is a commercially available probiotic preparation. These commercially probiotic preparations contain large numbers of viable microorganisms of either Lactobacillus sp., Bifidobacter sp. Streptococcus sp. or yeast. Consumption of the fiber preparation or probiotic by patients with constipation secondary to surgery or chronic antibiotic therapy, ulcerative colitis or Crohn's disease results in either a resolution of the symptoms or markedly improvement in symptoms without significant side effects.

Abstract: Strains of Lactobacillus which have been selected for their capability of reducing gastrointestinal inflammation, such as that due to Helicobacter pylori, and products derived from these strains, including agents for treatment or prophylaxis of inflammation associated with Helicobacter pylori for administration to humans and include conditioned media in which the selected strains have grown and protein-containing extracts of the conditioned media.

Abstract: The invention concerns the use of two lactobacteria for the preparation of immunomodulating compositions, in particular for the treatment and/or prevention of allergies and immunodeficiencies, and specifically use of the following two strains Lactobacillus salivarius I 1794 and Lactobacillus paracasei I 1688, alone or in combination, in the treatments indicated above.

Abstract: Disclosed is a method for producing an estrogen-like active intermediate (e.g., secoisolariciresinol) by culturing a lignan (e.g., a lignan derived from Eucommia ulmoides) together with a bacterium Lactobacillus acidophilus. Also disclosed a prophylactic/ameliorating agent for menopausal disorder and a functional beverage/food for preventing/ameliorating menopausal disorder comprising a lignan cultured together with a bacterium Lactobacillus acidophilus as an active ingredient.

Abstract: An ingestable composition for the photoprotection of the skin of pets which comprises a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one yeast and/or a carotenoid or derivative, included into an ingestable carrier.

Abstract: The present invention relates to the use of at least one strain of Lactobacillus plantarum chosen from the group comprising Lactobacillus plantarum 299, DSM 6595, Lactobacillus plantarum '299, DSM 9843, Lactobacillus plantarum HEAL 9, DSM 15312, Lactobacillus plantarum HEAL 19, DSM 15313, Lactobacillus plantarum HEAL 99, DSM 15316, and a part thereof, for the preparation of a composition for increasing the absorption of at least one kind of metal/metal ion in a mammal, preferably a human.

Abstract: In accordance with the present invention, a novel method for improving the stool characteristics, reducing the incidence of diarrhea, and firming the stool of a formula-fed infant of a formula-fed infant has been discovered. The method comprises administering to the infant at least one prebiotic and hydrolyzed pectin.

Abstract: The aim of the present invention is a method for the preparation of anallergic probiotic bacterial cultures.

Abstract: The present invention relates to a method of stimulating beta-defensins in skin cells which comprises applying to the skin cells an effective amount of a Lactobacillus extract or active fraction thereof.

Abstract: Fungicidal compositions are described, consisting of mixtures comprising a copper (II) salt of phosphorous acid and at least another metallic salt of phosphorous acid or consisting of mixtures comprising a copper (II) salt of phosphorous acid, alone or mixed with at least another metallic salt of phosphorous acid, and one or more fungicidal compounds, and their use for the control of phyto-pathogen fungi.

Abstract: The invention refers to a composition comprising one or more tannase-producing strains of Lactobacillus having the ability to adhere to the human intestinal mucosa in combination with tannin. New tannase-producing strains of Lactobacillus plantarum are a.

Abstract: A topical product to protect the skin from free radicals is disclosed in one embodiment of the invention as including a carrier medium for topical application to the skin. A sacrificial material that is compatible with the skin is interspersed with the carrier medium. This sacrificial material may be selected to react with free radicals within the skin. The sacrificial material may be further selected to react with water to produce hydrogen (a powerful antioxidant) and a reaction product that is also compatible with the skin. In this way, both the sacrificial material and the hydrogen will react with free radicals to provide protection against free radicals.

Abstract: The cosmetic use of at least an effective amount of hesperidin or of one of its derivatives in combination with at least an effective amount of at least one microorganism, in particular probiotic microorganism, or one of its fractions as agent for preventing a reduction in and/or for reinforcing the barrier function of the skin.

Abstract: The present invention relates to the field of probiotics. More particularly, the invention pertains to the use of a particular strain, Lactobacillus casei CNCM I-1518, which is present in Actimel®, for alleviating the symptoms of a delayed-type hypersensitivity reaction.

Abstract: Cosmetic use of an effective amount of at least one lysate of at least one microorganism of the genus Bifidobacterium species and/or a fraction thereof, for preventing and/or treating a skin disorder in the case of sensitive skin.

Abstract: The invention provides novel lactic acid bacteria having immunoregulating activities and usable in food and drinks, medicaments, and other applications. Specifically, the invention provides novel lactic acid bacteria separated from “Shibazuke,” one kind of traditional Kyoto pickles, and having immunoregulating activities. The lactic acid bacteria of the present invention belong to Lactobacillus pentosus.

Abstract: The present invention provides an antiallergic agent containing, as an active ingredient, lactic acid bacteria selected from the group consisting of lactic acid bacteria of the species Lactobacillus acidophilus, Lactobacillus fermentum, and combinations thereof. The antiallergic agent is capable of improving allergic diathesis by reducing the IgE level, which is contributive to development of Type I allergy, and is easy to take and highly safe. The present invention also provides use of the antiallergic agent for reducing allergy, and a method for reducing allergy using the antiallergic agent.

Abstract: A lactic bacteria strain that is exogenous to the oral microflora is selected for its ability to adhere the pellicle of the teeth and to produce a growth inhibition factor. This strain is used for the preparation of a composition intended for reducing dental plaque and for treating or preventing root caries and other diseases related to Actinomyces naeslundii in mammals.

Abstract: This invention relates to a preparation comprising a probiotic bacterial strain and a prebiotic mixture comprising 5-70 wt % of at least one N-acetylated oligosaccharide selected from the group comprising Ga1NAc?1,3Ga1?1,4G1c and Ga1?1,6Ga1NAc?1,3Ga1?1,4G1c, 20-95 wt % of at least one neutral oligosaccharide selected from the group comprising Ga1?1,6Ga1, Ga1?1,6Ga1?1,4G1c Ga1?1,6Ga1?1,6G1c, Ga1?1,3Ga1?1,3G1c, Ga1?1,3Ga1?1,4G1c, Ga1? 1,6Ga1? 1,6Ga1? 1,4G1c, Ga1? 1,6Ga1? 1,3Ga1? 1,4GIc Ga1? 1,3Ga1? 1,6Ga1? 1,4GIc and Ga1?1,3Ga1?1,3Ga1?1,4G1c and 2-50 wt % of at least one sialylated oligosaccharide selected from the group comprising NeuAc?2,3Ga1?1,4G1c and NeuAc?2,6Ga1?1,4G1c. The invention extends to food products comprising said preparation and to the use of the preparation in the prevention and treatment of infections.

Abstract: The present invention provides a method of preparing an edible product comprising non-viable bacteria providing a health benefit, the method comprising subjecting viable bacteria to at least two sub-lethal treatments to obtain the non-viable bacteria providing a health benefit, each sub-lethal treatment on its own not being sufficient to render the bacteria non-viable. The method porvides non-viable bacteria providing health benefits but which can conveniently be incorporated into a range of edible products.

Abstract: Applicants have discovered that a particular bacteriocin from the vaginal strain of Lactobacillus rhamnosus, lactocin (160), possesses a particularly advantageous activity against microorganisms associated with vaginal infections, and more specifically those associated with Bacterial Vaginosis (BV). Specifically, this compound is an effective and non-cytotoxic antibacterial agent that provides the basis for formulations MW for the improved prophylaxis and treatment of vaginal infections, and attendant reduction in the acquisition and proliferation of HIV. Applicants have isolated and purified the antimicrobial peptide lactocin (160) from a vaginal strain of L. rhamnosus. The peptide shows antibacterial activity in an agar-well bioassay against the major BV-associated bacteria, G. vaginalis and anaerobes (P bivia and Peptostreptococcus spp.) and does not inhibit the growth of lactobacilli species which are endogenous to a healthy vaginal environment.

Abstract: The present invention relates to a composition for preventing or treating arthritis, which comprises a lactic acid bacterium and collagen as major active ingredients. The present composition shows excellent prevention or treatment efficacies on arthritis of animal models. In addition, since the active ingredients used in the composition of this invention have been recognized to be safe to human, the present composition has considerable safety with enhanced immunomodulatory effect in patients with arthritis.

Abstract: The present invention relates to a composition which is in the form of a water-soluble anhydrous film comprising at least one water-soluble or water-dispersible film-forming polymer, and at least one live, in particular probiotic, microorganism. It also relates to a kit containing such a composition, as a combination with a secondary composition.

Abstract: Ferulate esterase producing bacterial strains or functional mutants thereof and methods of using ferulate esterase producing bacterial strains as forage additives are disclosed.

Abstract: The object is to provide: a safe immunomodulating agent which can be used as a pharmaceutical or a food material; a method for production of the immunomodulating agent; and a novel application of a coffee extract residue. Disclosed is an immunomodulating agent comprising a coffee extract as an active ingredient. Preferably, the coffee extract is an extract containing arabinogalactan. The immunomodulating effect of the immunomodulating agent relies on the promotion of the proliferation of an immunocompetent cell such as a macrophage. The immunocompetent cell is preferably any one selected from a macrophage like strain RAW264 or J774.1, a murine splenocyte, a murine peritoneal macrophage and a murine dendrocyte. A composition containing the immunomodulating agent can be used as a composition such as a pharmaceutical composition, a food composition and a cosmetic composition.